Live Biotherapeutic products -- a new regulatory approach for the safety assessment of a specific category of biological medicinal products

June 19, 2020

NARBONNE, France - An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of Live Biotherapeutic Products (LBPs). The publication represents the result of several face-to-face discussion sessions organized by the Pharmabiotic Research Institute (PRI).

Increased understanding of the relationship between the microbiota and its host highlighted the therapeutic potential of selected microorganisms to prevent or treat disease. However, while the pharmaceutical regulatory framework is harmonized at the EU level, obtaining a marketing authorization for LBPs remains very challenging. The safety assessment itself poses particular problems because of the potential sensitivity of the target population, the "live" nature and the complicated mode of action of LBPs.

While pharmaceutical guidelines for other biological products can be taken into account to design the relevant (non-)clinical development programmes, adapted guidelines on the safety assessment for LBPs are scattered and diverse. The authors of this article have made a concerted effort to establish a risk assessment roadmap for LBPs and propose appropriate solutions for non-clinical programmes and First in Human clinical safety trials.

"As developers have struggled when designing their LBP pre-clinical programmes, the industry can benefit from this very practical road map which takes into account the new concepts of 'quality' and 'development-by-design', usually applied to other biological medicinal products," says Dr. Magali Cordaillat-Simmons, corresponding author on the paper and Executive Director of the PRI.

Pr. Bruno Pot, Science Director for Yakult Europe and President of the PRI underlines, "The current paper is thought to respond to a real need in the field. Product developers, medical doctors, pharmacists, and patients might all benefit from clear procedures for the development of LBPs. The article could also help in the development of future regulatory pathways that will guarantee safety of LBPs for vulnerable populations, possibly helping groups of patients with high unmet medical needs."

The resulting document provides recommendations on regulatory approaches that will meet the drug authorities' expectations, weighing the existing guidelines for other biological drugs, but also focusing on strain characterization, involving history of use, antibiotic resistance and virulence testing, translocation potential, particular metabolic activities and potential drug-drug interactions. The paper reviews some newly developed research tools that could be considered, although often not yet validated. The approach proposed is largely supported by academic and industry representatives and will support future LBP safety assessment studies in Europe and the US.
Research article published in Frontiers in Medicine: Live Biotherapeutic Products, a road map for safety assessment
About the PRI (

The Pharmabiotic Research Institute (PRI) is a neutral and financially independent non-profit association (according to French law: Association loi 1901), who believes that the microbiome is the future of human medicine. The PRI applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members in the microbiome & human health space. Understanding the microbiome and its role in human health, however, represents a paradigm shift in how medicines will be developed, as innovation and industry often outpace regulation. The PRI was founded to make Microbiotic Medicinal Products (MMPs) a therapeutic reality in Europe. Our mission is to facilitate the conversation between European regulators and MMP developers and their partners. By being the main representative organization interrogated by the competent authorities regarding the future regulatory framework for MMPs, the PRI has become the first network for the European microbiome pharmaceutical supply chain, federating fundamental actors from the industry, such as stakeholders involved in the development, investment, production and commercialization of MMPs.

Contact: Joseph Simmons - M. +33 (0)6 61 24 57 17 -

Pharmabiotic Research Institute (PRI)

Related Safety Articles from Brightsurf:

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

How EU safety legislation has affected UK vapers
New research shows that vapers have been largely reassured by recent EU regulations, but some have been pushed to the black market for stronger hits.

Tunnel fire safety
With only minutes to respond, fire education really counts.

New study supports the safety of varenicline
A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT).

Advancing frozen food safety: Cornell develops novel food safety assessment tool
New research funded by the Frozen Food Foundation developed a modeling tool to assist the frozen food industry with understanding and managing listeriosis risks.

'Safety signals' may help slow down anxiety
For as many as one in three people, life events or situations that pose no real danger can spark a disabling fear, a hallmark of anxiety and stress-related disorders.

UQ researcher carving a new path for skier safety
A spectacular stack on a ski slope in Canada has led to a University of Queensland researcher determining a simple modification that could improve skier safety on the snow.

Nanomaterial safety on a nano budget
A Rice University laboratory develops and shares a low-cost method to safely handle the transfer of bulk carbon nanotubes and other nanomaterials.

Drexel-developed safety climate scale helps fire departments reach safety goals
A new safety scale, that effectively measures the safety climate of a fire department, has been developed by researchers from Drexel's Dornsife School of Public Health, according to a paper published today in the journal Safety Science.

Safety of overlapping surgeries
Overlapping surgeries, in which more than one procedure is performed by the same surgeon working in different operating rooms, have raised concerns about potential adverse outcomes.

Read More: Safety News and Safety Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to